# Novocuff

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novocuff

- Industry: Medical Devices & Equipment
- Headquarters: San Luis Obispo, US
- Website: www.novocuff.com/
- Total disclosed funding: $6.8M
- Latest round: Series A (Jun 4, 2024)
- Investors on record: 6

## About

Based in California, US, and founded in 2021 by CEO and co-founder Amelia Degenkolb, Novocuff, Inc. operates as a provider of minimally invasive devices intended to prevent preterm births by supporting healthcare professionals in improving pregnancy outcomes. In June 2024, Novocuff, Inc. raised USD 6.76 million in series A funding led by AXA IM Alts, with participation from Avestria Ventures, Laborie Medical Technologies Corp., Laerdal Million Lives Fund, March of Dimes Foundation, and RH Capital Partners.

The company provides a wide range of medical device solutions such as devices to delay labor for both singleton and multiple gestation pregnancies. Moreover, the firm's offerings include minimally invasive, non-surgical devices to stabilize and close the cervix, retain amniotic fluid, and sustain cervical length to extend pregnancy duration.

## Funding rounds

- Series A, Jun 4, 2024, $6.8M — AXA Investment Managers, March of Dimes Foundation, Laborie Medical Technologies Corp., RH Capital Partners, Avestria Ventures, Laerdal Million Lives Fund

## Investors

- AXA Investment Managers — Series A
- March of Dimes Foundation — Series A
- Laborie Medical Technologies Corp. — Series A
- RH Capital Partners (https://capitalatlas.ai/funds/rh-capital-partners) — Series A
- Avestria Ventures (https://capitalatlas.ai/funds/avestria-ventures) — Series A
- Laerdal Million Lives Fund (https://capitalatlas.ai/funds/laerdal-million-lives-fund) — Series A